SCHEMBL4113010

SCHEMBL4113010

Cc1ccc(NC(=O)[C@H](O)[C@@H](O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.48
HPSE Q9Y251 1/20 0.47
THRB P10828 1/20 0.46
MAPT P10636 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 2/20 0.44
TP53 P04637 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDR P35968 2/20 0.43
PLAU P00749 1/20 0.43
BAZ1A Q9NRL2 1/20 0.43
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
ABL1 P00519 1/20 0.42
FABP6 P51161 1/20 0.42
ALDH1A1 P00352 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4100714 0.89 ABL1 (0.52) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4113916 0.88 NR2E3 (0.45) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL4108132 0.88 HTR3E (0.54) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL12313735 0.88 KDR (0.46) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4115769 0.88 KDR (0.46) MAPTMEN1KMT2ALMNAGAA
SCHEMBL8214601 0.88 PLAU (0.43) MAPTMEN1KMT2AGAATP53
SCHEMBL4112324 0.84 ALDH1A1 (0.60) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4100589 0.83 MAPT (0.52) EGFRHPSETHRBMAPTMEN1
SCHEMBL4115801 0.83 GRIN1 (0.53) MAPTLMNASMN1; SMN2KDRABL1
SCHEMBL4102032 0.81 MAPT (0.47) MAPTMEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069288-B1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2014-03-26 EP claimed
US-8263621-B2 Tartrate derivatives for use as coagulation factor IXa inhibitors SANOFI (FR) 2012-09-11 US claimed
US-20090233961-A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
EP-2069288-B1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2014-03-26 EP disclosed
US-8263621-B2 Tartrate derivatives for use as coagulation factor IXa inhibitors SANOFI (FR) 2012-09-11 US disclosed
US-8263621-B2 Tartrate derivatives for use as coagulation factor IXa inhibitors SANOFI (FR) 2012-09-11 US disclosed
US-20090233961-A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US disclosed
US-20090233961-A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US disclosed
WO-2008031508-A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI-AVENTIS (FR) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233961-A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, TFPI2, F9 EGFR 791/4885HPSE 418/4885THRB 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.